News | June 02, 2008

GE Focuses on PET-VCAR Innovations at ASCO

June 3, 2008 – GE showcased at ASCO its latest advances in molecular imaging technologies such as the IN Cell Analyzer, Positron Emission Tomography/Volume Computer Assisted Reading (PET-VCAR) and Fastlab automated PET radiopharmacy, aiming to help healthcare providers understand the molecular root of diseases and explore new paths for detecting, treating and monitoring illnesses earlier.

PET-VCAR is a complement to GE’s approach to personal patient management. The system reportedly helps optimize tumor management by enabling early quantification and evaluation of treatment effectiveness, a valuable tool for treatment planning. It features workflow enhancements for both single and multi-exam review, and includes exam-to-exam auto-registration; tumor segmentation and quantification; and multiplanar image review.

IN Cell Analyzer System from GE’s Life Science Division, represents a complete solution for high-content sub-cellular analysis. Used in research and drug discovery, the system performs assays directly inside cells and uses image analysis techniques to give quantitative results for those assays for each individual cell. The power of the IN Cell Analyzer comes from using the high throughput it delivers to analyze thousands of cells under different conditions to generate statistically robust data.

Fastlab is the first multitracer PET chemistry synthesis platform to feature a cassette that incorporates premeasured, preloaded reagents—an innovation that reportedly delivers higher yields, improved reproducibility and faster synthesis than any other platform. It is designed to accommodate different chemistries, facilitating the production of multiple PET tracers. The first application launched on the platform is FDG. GE Healthcare is planning to expand the utility of the platform by developing a range of other radiopharmaceuticals, including GE Healthcare proprietary diagnostic imaging agents.

The GE Signa Vibrant is a dedicated 1.5T breast MR scanner utilizing High Definition technology and applications specifically designed for breast MR, including: VIBRANT acquisition, BREASE spectroscopy, integrated CADstream (manufactured by Confirma) and a specially designed breast MR patient table designed to provide optimal imaging and outstanding access for intervention. Signa Vibrant’s design is said to be ideally suited for the environment of many breast-imaging centers.

GE helps physicians take aim at cancer with their Advanced Imaging technologies for radiation therapy planning. GE’s radiation therapy solutions include advanced imaging technologies with LightSpeedRT16 wide-bore multislice CT simulator, Discovery PET-CT scanner, Signa MR system and radiation oncology simulation software, providing tools geared at maximizing the potential of new treatment delivery technologies.

GE also showcased solutions from its Centricity portfolio, including the Centricity Electronic Medical Record, Practice Solution and PACS. With users reportedly ranging from the nation’s largest healthcare organization to the solo practitioner, the Centricity EMR is an ambulatory system relied on by more than 30,000 clinicians nationwide. Centricity Practice Solution is a completely integrated clinical and financial management solution aimed to provide a singular approach to a more efficient, high quality practice – extending from the patient’s first visit to final reimbursement.

For more information: www.gehealthcare.com

Related Content

Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...
Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...